Sunshine Heart (CHFS) Receiving Somewhat Favorable News Coverage, Study Shows

News headlines about Sunshine Heart (NASDAQ:CHFS) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sunshine Heart earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 43.8457276071379 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Sunshine Heart (NASDAQ CHFS) opened at 0.565 on Tuesday. Sunshine Heart has a 52 week low of $0.51 and a 52 week high of $28.80. The firm’s 50-day moving average is $0.69 and its 200 day moving average is $1.29. The company’s market capitalization is $7.07 million.

A number of analysts recently weighed in on CHFS shares. Ladenburg Thalmann Financial Services started coverage on shares of Sunshine Heart in a research note on Thursday, June 29th. They issued a “buy” rating and a $3.25 target price on the stock. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

ILLEGAL ACTIVITY WARNING: “Sunshine Heart (CHFS) Receiving Somewhat Favorable News Coverage, Study Shows” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/sunshine-heart-chfs-receiving-somewhat-favorable-news-coverage-study-shows.html.

In other news, major shareholder Ki Yong Choi bought 78,211 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was bought at an average cost of $0.64 per share, for a total transaction of $50,055.04. Following the transaction, the insider now owns 1,731,464 shares of the company’s stock, valued at $1,108,136.96. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by insiders.

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Shares of Sunshine Heart (NASDAQ CHFS) opened at 0.565 on Tuesday. Sunshine Heart has a 52 week low of $0.51 and a 52 week high of $28.80. The firm’s 50-day moving average is $0.69 and its 200 day moving average is $1.29. The company’s market capitalization is $7.07 million.

A number of analysts recently weighed in on CHFS shares. Ladenburg Thalmann Financial Services started coverage on shares of Sunshine Heart in a research note on Thursday, June 29th. They issued a “buy” rating and a $3.25 target price on the stock. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

ILLEGAL ACTIVITY WARNING: “Sunshine Heart (CHFS) Receiving Somewhat Favorable News Coverage, Study Shows” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/sunshine-heart-chfs-receiving-somewhat-favorable-news-coverage-study-shows.html.

In other news, major shareholder Ki Yong Choi bought 78,211 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was bought at an average cost of $0.64 per share, for a total transaction of $50,055.04. Following the transaction, the insider now owns 1,731,464 shares of the company’s stock, valued at $1,108,136.96. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by insiders.

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Insider Buying and Selling by Quarter for Sunshine Heart (NASDAQ:CHFS)

Receive News & Ratings for Sunshine Heart Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart Inc and related companies with MarketBeat.com's FREE daily email newsletter.